Abiomed Ár/értékesítés
Mi az Abiomed Ár/értékesítés?
A Ár/értékesítés az Abiomed Inc. - 16.10
Mi a Ár/értékesítés meghatározása?
Az ár / árbevétel arány a vállalat részvényeinek árbevételéhez képest.
The price to sales ratio, Price/Sales ratio, P/S ratio, or PSR, is a valuation metric for stocks. It is calculated by dividing the company's market cap by the revenue in the most recent year. It can also be calculated by dividing the per-share stock price by per-share revenue. The price to sales ratio is for trailing twelve months so the reported sales are for the four previous quarters. Longer time periods can be examined at times.
A smaller price to sales ratio is usually thought to be a better investment since the investor is paying less for each unit of sales. However, sales do not reveal the whole picture, as the company may be unprofitable with a low P/S ratio. Because of the limitations, this ratio is usually used only for unprofitable companies, since they don't have a price to earnings ratio (P/E ratio). The metric can be used to determine the value of a stock relative to its past performance. It may also be used to determine relative valuation of a sector or the market as a whole.
Price to sales ratios vary greatly between sectors, so they are most useful in comparing similar stocks within a sector or sub-sector. Comparing P/S ratios carries the implicit assumption that all firms in the comparison have an identical capital structure.
Ár/értékesítés a Health Care szektor a NASDAQ-on cégekben a Abiomed -hoz képest
Mit csinál Abiomed?
Abiomed Europe GmbH, Aachen / Germany, as affiliate of Abiomed Inc. headquartered in Danvers, Massachusetts, USA, is a leading medical technology company in the field of circulatory support. Its products aim to enable heart recovery by improving blood circulation and/or heart pump function.
ár/értékesítés -hoz hasonló cégek Abiomed
- Hibernia REIT Plc nak Ár/értékesítés 16.01 van
- Stampede Capital nak Ár/értékesítés 16.01 van
- StarPower Semiconductor nak Ár/értékesítés 16.02 van
- Creative Eye nak Ár/értékesítés 16.05 van
- 3i Infotech nak Ár/értékesítés 16.07 van
- PIMCO Corporate & Income Strategy Fund nak Ár/értékesítés 16.10 van
- Abiomed nak Ár/értékesítés 16.10 van
- Beijing Hotgen Biotech Co nak Ár/értékesítés 16.10 van
- Wheelock and nak Ár/értékesítés 16.12 van
- Vantage Towers Ag Na O.N nak Ár/értékesítés 16.14 van
- Immobilière Dassault SA nak Ár/értékesítés 16.14 van
- WAM Leaders nak Ár/értékesítés 16.16 van
- Orthocell nak Ár/értékesítés 16.17 van